On January 7, 2026, InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced a global strategic collaboration and licensing agreement, and equity investment, with Eli Lilly and Company to discover novel oncology treatments using InduPro’s proximity-guided platform. Under the terms of the agreement, InduPro and Eli Lilly will collaborate on up to three targets, for a total deal value of up to approximately $950 million. Wilson Sonsini Goodrich & Rosati advised InduPro on the transaction.

The Wilson Sonsini team that advised InduPro included Lowell Segal, Christina Poulsen, Ken Clark, Rachel Slyker, Alex Weber, and Steven Song.

For more information, please see InduPro’s press release. Additional coverage can be found on Fierce Biotech.